Madrid, Spain and Heidelberg, Germany, 3 August 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today reported results for the second quarter of 2017 and six-month period ended 30 June 2017. “In the first half of 2017, we continued to actively implement our Grow, Buy, and Build strategy, highlighted by the successful acquisition of two profitable companies – C.B.S. Scientific and Innova Biosciences,” said Dr. Heikki Lanckriet, CEO and CSO. “We also continued to introduce new products and services and expanded our access to the growing Chinese market with the signing of a second OEM deal with TANON. In the months ahead, we expect to continue to grow and advance our business with a focus on new product launches.”
